Adam's Take

Adam's Take By Adam Feuerstein

Aytu Bioscience capitalizes on coronavirus antibody test demand, but the good times won’t last

Adam's Take By Adam Feuerstein

Athersys pivots a stem cell therapy to Covid-19, but prior data offer little confidence

Adam's Take By Adam Feuerstein

Biotech in the time of coronavirus: The return of mergers, acquisitions, and deals

Adam's Take By Adam Feuerstein

Biotech in the time of coronavirus: Pondering the future of ‘JPM Week’

Adam's Take By Adam Feuerstein

Biotech in the time of the coronavirus: With China returning to work, preclinical companies ramping back up

Adam's Take By Adam Feuerstein

Biotech in the time of the coronavirus: Stocks are down, but optimistic investors see opportunities ahead

Adam's Take By Adam Feuerstein

Biotech in the time of the coronavirus: Disruptions continue, but there’s some good news, too

Adam's Take By Adam Feuerstein

Biotech in the time of the coronavirus: A semi-regular column on the outbreak’s impact on drug makers

transmission electron micrograph covid19

Adam's Take By Adam Feuerstein

Biotech, bracing for widespread coronavirus fallout, hopes for the best and prepares for the worst

Adam's Take By Adam Feuerstein

TG Therapeutics cops to another blood cancer drug trial delay, as excuses wear thin

Adam's Take By Adam Feuerstein

Allakos is running clinical trials in reverse, critics say, raising questions about its digestive disease drug

Adam's Take By Adam Feuerstein

‘Pharma doesn’t like fish oil’: Wall Street funds sold Amarin after big win with heart drug

Adam's Take By Adam Feuerstein

Investor impatience with Gilead reclamation project sparks acquisition chatter

Adam's Take By Adam Feuerstein

If biotech had a Mount Rushmore, whose heads would you chisel in the granite?

Adam's Take By Adam Feuerstein

As Biogen gets squishy on timing for an aducanumab filing, the clock is ticking

Adam's Take By Adam Feuerstein

The truth about JPM: Less is more

Adam's Take By Adam Feuerstein

All talk, no M&A makes for a down JPM Day

Adam's Take By Adam Feuerstein

Two days into the ‘real’ start of 2020 and all those expected biotech buyouts are still MIA

Adam's Take By Adam Feuerstein

Biotech 2020 preview: Takeover targets, notable drug launches, and genome editing readouts

Biotech By Adam Feuerstein and Matthew Herper

STAT’s guide to the most important, beneficial drugs approved in the past decade

Adam's Take By Adam Feuerstein

Maraganore victorious in best biopharma CEO tally; Vounatsos tops worst list

Adam's Take By Adam Feuerstein

And now, your nominees for worst biopharma CEO of 2019. Let the voting begin!

Adam's Take By Adam Feuerstein

Here are the nominees for best biopharma CEO of 2019. Vote for your favorite!

Adam's Take By Adam Feuerstein

The good, the bad, and the really, really ugly behind Sarepta’s drug approval

Adam's Take By Adam Feuerstein

Most Read

A moment of truth arrives for CytoDyn’s Covid-19 drug. Don’t let spin obscure it

CytoDyn’s Covid-19 drug troubles escalate: Efficacy data are missing from study

FDA refuses application for HIV drug from CytoDyn, raising more questions about its credibility

Moderna’s skyrocketing market value is an indictment of the U.S. Covid-19 response

CytoDyn CEO made $12M from his stock sale, and his explanation raises more questions

Applied Therapeutics amends investor deck, bolstering accusations made by anonymous critic

Moderna carries a big-boy market valuation now, so it shouldn’t act like a biotech penny stock

ASCO 2020 takeaways: AstraZeneca does a star turn, KRAS fizzles, and cell therapy shows progress

All Coverage

Aytu Bioscience capitalizes on coronavirus antibody test demand, but the good times won’t last

Athersys pivots a stem cell therapy to Covid-19, but prior data offer little confidence

Biotech in the time of coronavirus: The return of mergers, acquisitions, and deals

Biotech in the time of coronavirus: Pondering the future of ‘JPM Week’

Biotech in the time of the coronavirus: With China returning to work, preclinical companies ramping back up

Biotech in the time of the coronavirus: Stocks are down, but optimistic investors see opportunities ahead

Biotech in the time of the coronavirus: Disruptions continue, but there’s some good news, too

Biotech in the time of the coronavirus: A semi-regular column on the outbreak’s impact on drug makers

Biotech, bracing for widespread coronavirus fallout, hopes for the best and prepares for the worst

TG Therapeutics cops to another blood cancer drug trial delay, as excuses wear thin

Allakos is running clinical trials in reverse, critics say, raising questions about its digestive disease drug

‘Pharma doesn’t like fish oil’: Wall Street funds sold Amarin after big win with heart drug

Investor impatience with Gilead reclamation project sparks acquisition chatter

If biotech had a Mount Rushmore, whose heads would you chisel in the granite?

As Biogen gets squishy on timing for an aducanumab filing, the clock is ticking

The truth about JPM: Less is more

All talk, no M&A makes for a down JPM Day

Two days into the ‘real’ start of 2020 and all those expected biotech buyouts are still MIA

Biotech 2020 preview: Takeover targets, notable drug launches, and genome editing readouts

STAT’s guide to the most important, beneficial drugs approved in the past decade

Maraganore victorious in best biopharma CEO tally; Vounatsos tops worst list

And now, your nominees for worst biopharma CEO of 2019. Let the voting begin!

Here are the nominees for best biopharma CEO of 2019. Vote for your favorite!

The good, the bad, and the really, really ugly behind Sarepta’s drug approval

Cel-Sci is publicly upbeat about its cancer drug. Privately it’s trying to sell stock

Adam’s Take

Most Read

All Coverage